{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Alvotech Shares Plunge to New 52-Week Low of $4.70
Alvotech, a small-cap pharmaceutical company, has reached a new 52-week low, reflecting a substantial decline in stock performance over the past year. Despite impressive growth in net sales and operating profit, the company faces financial challenges, including a negative book value and a high debt-to-equity ratio.
Alvotech Stock Hits Day Low of $4.81 Amid Price Pressure
Alvotech, a small-cap pharmaceutical company, faced significant stock volatility on November 3, 2025, with a notable decline in its share price. Over the past year, the company has struggled with a negative book value and weak debt servicing capabilities, despite a substantial increase in profits.
Alvotech Shares Plunge to New 52-Week Low of $4.81
Alvotech has reached a new 52-week low, reflecting significant challenges in its financial performance. Despite impressive growth rates in net sales and operating profit over the past five years, the company has struggled with declining stock value and negative financial metrics, including a concerning return on equity.
Alvotech Experiences Revision in Stock Evaluation Amid Mixed Performance Indicators
Alvotech, a small-cap pharmaceutical company, has experienced a challenging year with a significant decline in stock performance. Despite recent weekly and monthly gains, the overall year-to-date return remains negative. Technical indicators present a mixed outlook, reflecting ongoing volatility in the market.
Alvotech Hits Day High with 8.61% Surge Amid Intraday Trading Boost
Alvotech, a small-cap pharmaceutical company, experienced notable stock activity today, reaching an intraday high. However, it has struggled recently, with significant declines over the past week and year-to-date. Financial metrics reveal a negative book value and weak fundamental strength, highlighting ongoing challenges in the market.
Is Alvotech technically bullish or bearish?
As of July 31, 2025, Alvotech's trend has shifted to bearish, indicated by negative signals from MACD, Bollinger Bands, and moving averages, while it has significantly underperformed the S&P 500 with a year-to-date return of -40.89%.
Is Alvotech overvalued or undervalued?
As of November 16, 2022, Alvotech is considered overvalued and risky due to its high P/E ratio of 33 compared to the industry average, negative book value, and poor stock performance, with a year-to-date return of -30.99%.
Is Alvotech technically bullish or bearish?
As of June 17, 2025, Alvotech's trend has shifted to bearish with moderate strength, driven by daily moving averages and Bollinger Bands indicating bearish momentum, despite mixed signals from the MACD across different time frames and significant underperformance against the S&P 500.
What does Alvotech do?
Alvotech is a small-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales and profit of $110 million and a market cap of $2.78 billion. Key metrics include a P/E ratio of 33.00 and a return on equity of -31.94%.
How big is Alvotech?
As of Jun 18, Alvotech has a market capitalization of 2,782.65 million and reported net sales of 562.75 million and net profit of 96.54 million over the latest four quarters. Shareholder's funds are at -412.77 million, with total assets of 1,221.40 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
